<p>This week, Health Canada approved two generic versions of Ozempic. This will mean reduced cost, and therefore broader access, to a medication that’s been prohibitively expensive for many.&nbsp;</p><p><br></p><p>What questions do you have about accessing and using GLP1 drugs? What do you want to know about both the risks and benefits of broader access to these drugs?</p><p><br></p><p>Here to field your questions are Jennifer Lake, assistant professor at the Leslie Dan Faculty of Pharmacy at the University of Toronto, and Dr. Megha Poddar, assistant clinical professor at McMaster University.</p>